Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587908 | 0.86 | GABRA1 (0.38) | GABRA1GABRB2KDM4ETAAR1ALDH1A1 | |
| SCHEMBL91337 | 0.85 | KDM4E (0.45) | GABRA1GABRB2KDM4ETAAR1ALDH1A1 | |
| SCHEMBL14140079 | 0.85 | GABRA1 (0.41) | GABRA1GABRB2KDM4ETAAR1HTR1A | |
| SCHEMBL20252575 | 0.85 | TAAR1 (0.43) | GABRA1GABRB2KDM4ETAAR1HTR1A | |
| SCHEMBL16962802 | 0.85 | GABRA1 (0.41) | GABRA1GABRB2KDM4ETAAR1ALDH1A1 | |
| SCHEMBL17857328 | 0.85 | HTT (0.39) | GABRA1GABRB2KDM4ETAAR1ALDH1A1 | |
| SCHEMBL17858593 | 0.85 | HTT (0.39) | GABRA1GABRB2KDM4ETAAR1ALDH1A1 | |
| SCHEMBL320965 | 0.85 | GABRA1 (0.46) | GABRA1GABRB2KDM4ETAAR1HTR1A | |
| SCHEMBL18984003 | 0.85 | GABRA1 (0.46) | GABRA1GABRB2KDM4ETAAR1HTR1A | |
| SCHEMBL19446544 | 0.85 | GABRA1 (0.41) | GABRA1GABRB2KDM4ETAAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4238962-A1 | METHOD FOR PRODUCING DIIMINOPYRROLE COMPOUND | Godo Shigen Co., Ltd. (JP) | 2023-09-06 | — | — | EP | disclosed |
| CN-105764897-A | Use of macrocylic picolinamides as fungicides | 美国陶氏益农公司 | 2016-07-13 | — | — | CN | disclosed |
| CN-105745205-A | Use of macrocyclic picolinamides as fungicides | 美国陶氏益农公司 | 2016-07-06 | — | — | CN | disclosed |
| US-9035056-B2 | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035056-B2 | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8906925-B2 | Pyrido[4,3-B]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906925-B2 | Pyrido[4,3-B]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140206711-A1 | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206711-A1 | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20130225558-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-29 | — | — | US | disclosed |
| US-20130225558-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-29 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20120211082-A1 | PHOTOELECTRIC CONVERSION DEVICE AND SOLAR CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-23 | — | — | US | disclosed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-7084077-B2 | Method of fabricating multilayer interconnect wiring structure having low dielectric constant insulator film with enhanced adhesivity | KABUSHIKI KAISHA TOSHIBA (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20050085097-A1 | Method of fabricating multilayer interconnect wiring structure having low dielectric constant insulator film with enhanced adhesivity | SEMICONDUCTOR LEADING EDGE TECHNOLOGIES, INC. (JP) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | GABRA1 110/4885GABRB2 153/4885KDM4E 318/4885 |
| US-20140206711-A1 | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE | HTR1B, HTR2B, HTR2A | GABRA1 332/4885GABRB2 110/4885KDM4E 3331/4885 |
| US-20130225558-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | GABRA1 123/4885GABRB2 99/4885KDM4E 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.